Valuation: Black Diamond Therapeutics, Inc.

Market Cap 121M 105M 97.94M 89.33M 168M 11.51B 171M 1.15B 450M 5.76B 453M 443M 19.21B P/E 2026 *
-3.32x
P/E 2027 * -2.25x
Enterprise Value 121M 105M 97.94M 89.33M 168M 11.51B 171M 1.15B 450M 5.76B 453M 443M 19.21B EV / Sales 2026 *
16.9x
EV / Sales 2027 * -
Free-Float
99.35%
Yield 2026 *
-
Yield 2027 * -
1 day+0.48%
1 week+17.32%
Current month+24.26%
1 month+9.95%
3 months-25.80%
6 months-4.11%
Current year-13.58%
1 week 1.9
Extreme 1.905
2.14
1 month 1.62
Extreme 1.62
2.14
Current year 1.6
Extreme 1.6
3.97
1 year 1.6
Extreme 1.6
4.94
3 years 1.2
Extreme 1.195
7.66
5 years 1.18
Extreme 1.18
10.47
10 years 1.18
Extreme 1.18
46.25
Manager TitleAgeSince
Chief Executive Officer 62 16/09/2023
Chief Tech/Sci/R&D Officer 51 11/08/2021
Director of Finance/CFO 41 07/10/2024
Director TitleAgeSince
Director/Board Member 61 01/03/2017
Director/Board Member 47 01/12/2019
Director/Board Member 49 01/12/2018
Date Insider Type Main position Quantity % Market Cap.
20/3/26 Free

Director

6,919 0.0121%
21/1/26 Free

Chief Technology Officer

250,000 0.4388%
21/1/26 Free

Founder

250,000 0.4388%
Change 5-day change 1-year change 3-year change Capi.($)
+0.48%+17.32%-17.32%-36.94% 121M
-0.73%+7.82%+73.81%+102.34% 70.1B
-0.34%+0.61%+37.69%+65.92% 54.93B
-0.22%+33.59%+8.43%+489.75% 28.89B
0.00%+10.29%+48.18%+7.26% 23.9B
-0.06%+0.61%-16.45%-13.26% 23.3B
-1.37%+7.87%+251.71%+464.53% 18.41B
-0.39%+8.20%+41.29%-19.88% 18.77B
-0.95%+3.05%+25.12%+617.12% 16.1B
-1.85%-11.15%+32.75%+134.11% 12.48B
Average -0.56%+9.27%+48.52%+181.09% 26.7B
Weighted average by Cap. -0.57%+9.43%+54.22%+167.00%

Financials

2026 *2027 *
Net sales 7.14M 6.19M 5.8M 5.29M 9.94M 681M 10.1M 68.2M 26.66M 341M 26.82M 26.24M 1.14B -
Net income -37.69M -32.65M -30.6M -27.91M -52.46M -3.59B -53.27M -360M -141M -1.8B -142M -138M -6B -62.63M -54.26M -50.84M -46.37M -87.18M -5.97B -88.52M -598M -234M -2.99B -235M -230M -9.97B
Net Debt - -
Logo Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The Company is advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. Its BDTX-4933 pipeline product is out-licensed to Servier. BDTX-4933 is designed to target RAS and RAF alterations in solid tumors. It is exploring partnership opportunities for its FGFR2/3 selective development candidate BDTX-4876.
Employees
21
Date Price Change Volume
12/08/26 US$2.100 +0.48% 645,616
11/08/26 US$2.090 +5.56% 812,736
10/08/26 US$1.980 +1.54% 664,997
07/08/26 US$1.950 +1.56% 599,940
06/08/26 US$1.920 +7.26% 748,139
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
2.100USD
Average target price
10.00USD
Spread / Average Target
+376.19%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BDTX Stock